# A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

> **NCT00157534** · PHASE2 · COMPLETED · sponsor: **BioWest Therapeutics Inc** · enrollment: 43 (—)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Celgosivir

## Key facts

- **NCT ID:** NCT00157534
- **Lead sponsor:** BioWest Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 43 (—)
- **Last updated:** 2005-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157534, "A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00157534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*